

1. History, diagnosis, and epidemiology

- 1: The history of rheumatoid arthritis, *David L. Scott*
- 2: Diagnosis, *Daniel Aletaha and Helga Radner*
- 3: The descriptive epidemiology of rheumatoid arthritis, *James Gwinnutt and Deborah Symmons*
- 4: Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy, *Lars Klareskog and Lars Alfredsson*

2. Pathogenesis

- 5: Genetics and epigenetics of rheumatoid arthritis, *Anne Barton*
- 6: Dysregulation of synovial fibroblasts in rheumatoid arthritis, *Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley*
- 7: Autoantibodies in rheumatoid arthritis, *Tom W. J. Huizinga*
- 8: Dendritic cells and T cells in rheumatoid arthritis, *Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas*
- 9: Mechanisms of bone and cartilage destruction, *Ukrike Steffen and Georg Schett*
- 10: Cytokines and other mediators, *Marina Frleta-Gilchrist and Iain B. McInnes*

3. Clinical presentation

- 11: Clinical features of rheumatoid arthritis, *Annette van der Helm-van Mil*
- 12: Pre-rheumatoid arthritis, *Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg*
- 13: Non-articular manifestations of rheumatoid arthritis, *Katherine MacDonald, Jennifer Hannah, and James Galloway*
- 14: Comorbidity in rheumatoid arthritis, *Kimme Hyrich and Sarah Skeoch*

4. Disease assessment

- 15: Disease activity assessment in rheumatoid arthritis, *Josef Smolen*
- 16: Synovial biopsies, *Douglas Veale and Ursula Fearon*
- 17: Radiography in rheumatoid arthritis, *Charles Peterfy, Philip Conaghan, and Mikkel Østergaard*
- 18: Ultrasound in rheumatoid arthritis, *Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin*
- 19: MRI in rheumatoid arthritis, *Charles Peterfy, Philip Conaghan, and Mikkel Østergaard*

5. Impact on life

- 20: Patient physical function in rheumatoid arthritis, *Kathryn A. Gibson and Theodore Pincus*
- 21: Fatigue, *Emma Dures and Neil Basu*
- 22: Health economics, *David L. Scott and Allan Wailoo*
- 23: Rheumatoid arthritis and work, *Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway*

6. Non-drug treatments

- 24: Exercise, *Lindsay Bearne and Christina Opava*
- 25: Foot health, *Heidi Siddle and Anthony Redmond*

26:Occupational therapy, *Alison Hammond, Joanne Adams, and Yeliz Prior*

27:Self-management: a patient's perspective, *Marieke M.J.H. Voshaar*

7. Drug treatments

28:Analgesics, Opioids, and NSAIDs, *Mark D Russell and Nidhi Sofat*

29:Glucocorticoids, *Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and José A. P. da Silva*

30:Conventional disease modifying drugs, *David L. Scott*

31:Tumour necrosis factor inhibitors, *Peter Taylor and Nehal Narayan*

32:Interleukin-6 inhibitors, *Neelam Hassan and Ernest Choy*

33:B-cell therapies, *Yuzaiful Yusof, Edward Vital, and Maya Buch*

34:Biosimilars, *Vibeke Strand, Jeffrey Kaine, and John Isaacs*

35:Immunogenicity in response to biologic agents, *Meghna Jani, John Isaacs, and Vibeke Strand*

36:The use of JAK inhibitors in the treatment of rheumatoid arthritis, *Katie Bechman, James Galloway, and Peter Taylor*

37:Combination therapy in rheumatoid arthritis, *Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler*

38:Translation of new therapies: from bench to bedside, *Jeremy Sokolove*

39:Adverse events in clinical studies in rheumatoid arthritis, *James Galloway and Mark Yates*

8. Management and outcomes

40:Prevention of rheumatoid arthritis, *Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope*

41:Treatment targets and remission, *Kenneth F Baker and Arthur G Pratt*

42:Clinical outcomes, *David L. Scott*

43:Clinical guidelines, *Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien*

44:European biologics registers, *Angela Zink and Anja Strangfeld*

45:Voluntary patient registries, *Jeff Greenberg and Sheetal Patel*